2026Q1
| Insider | Role (last 12 mo) | Shares held | Filed at |
|---|---|---|---|
| Schuetz Thomas J. | CEO | 6,436,800 | Nov 18, 2025 |
| Anderson Errik | — | 5,290,270 | Jun 29, 2020 |
| Tompkins Mark N. | — | 4,750,000 | Jul 30, 2018 |
| Gordon Carl L | Director | 3,571,428 | Nov 8, 2021 |
| Orbimed Advisors Llc | Director | 3,571,428 | Nov 8, 2021 |
| Exec date | Filing date | Insider | Role | Signal | Confidence | Shares | % of shares | Under plan? | Amount (USD) |
|---|---|---|---|---|---|---|---|---|---|
| Feb 8, 2026 | Feb 10, 2026 | Schuetz Thomas J. | CEO | Sell | 45.0 | -36,687 | -0.55% | ✗ | $239.2K |
| Jan 9, 2026 | Jan 12, 2026 | Schuetz Thomas J. | CEO | Sell | 42.5 | -46,777 | -0.70% | ✗ | $250.3K |
| Jan 2, 2026 | Jan 5, 2026 | Shin Barry | CFO | Neutral | 90.0 | +125,000 | 31.25% | ✗ | - |
| Jan 2, 2026 | Jan 5, 2026 | Sirard Cynthia | Chief Medical Officer | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jan 2, 2026 | Jan 5, 2026 | Schuetz Thomas J. | CEO | Neutral | 82.5 | +250,000 | 3.88% | ✗ | - |
| Jan 2, 2026 | Jan 5, 2026 | Prasad Arjun | Chief Commercial Officer | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jan 2, 2026 | Jan 5, 2026 | LINDAHL RICHARD S | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jan 2, 2026 | Jan 5, 2026 | Chiniara Ellen | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jan 2, 2026 | Jan 5, 2026 | Lerner Neil | Chief Accounting Officer | Neutral | 90.0 | +62,500 | 19.53% | ✗ | - |
| Jan 2, 2026 | Jan 5, 2026 | GRAY MARY ANN | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jan 2, 2026 | Jan 5, 2026 | Boylan James P | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jan 2, 2026 | Jan 5, 2026 | GORDON CARL L | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jan 2, 2026 | Jan 5, 2026 | Ferneau Philip | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Jan 2, 2026 | Jan 5, 2026 | Anderman Jonathan | General Counsel | Neutral | 90.0 | +150,000 | 714.29% | ✗ | - |
| Jan 5, 2026 | Sirard Cynthia | Chief Medical Officer | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Jan 5, 2026 | Prasad Arjun | Chief Commercial Officer | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Nov 16, 2025 | Nov 18, 2025 | Schuetz Thomas J. | CEO | Sell | 45.0 | -44,025 | -0.68% | ✗ | $212.6K |
| May 27, 2025 | May 27, 2025 | Schuetz Thomas J. | CEO | Buy | 56.3 | +10,000 | 0.15% | ✗ | $21.1K |
| Apr 9, 2025 | Apr 11, 2025 | GORDON CARL L | Director | Sell | 16.3 | -3,571,428 | -100.00% | ✗ | $5.7M |
| Apr 9, 2025 | Apr 11, 2025 | ORBIMED ADVISORS LLC | Director | Sell | 16.3 | -3,571,428 | -100.00% | ✗ | $5.7M |
| Apr 7, 2025 | Apr 8, 2025 | Anderman Jonathan | Gen Counsel & Corporate Sec | Buy | 91.3 | +20,000 | 2000.00% | ✗ | $30.8K |
| Apr 7, 2025 | Apr 8, 2025 | Lerner Neil | CHIEF ACCOUNTING OFFICER | Buy | 86.3 | +20,000 | 6.67% | ✗ | $28.4K |
| Feb 11, 2025 | Feb 13, 2025 | Shin Barry | CFO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Feb 11, 2025 | Feb 13, 2025 | Schuetz Thomas J. | CEO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Feb 11, 2025 | Feb 13, 2025 | LINDAHL RICHARD S | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Feb 11, 2025 | Feb 13, 2025 | Lerner Neil | SVP, CAO | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Feb 11, 2025 | Feb 13, 2025 | GRAY MARY ANN | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Feb 11, 2025 | Feb 13, 2025 | Ferneau Philip | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Feb 11, 2025 | Feb 13, 2025 | Chiniara Ellen | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Feb 11, 2025 | Feb 13, 2025 | Anderman Jonathan | Sr VP, Gen Counsel & Corp Sec | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Feb 11, 2025 | Feb 13, 2025 | GORDON CARL L | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Feb 11, 2025 | Feb 13, 2025 | Boylan James P | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Feb 8, 2025 | Feb 11, 2025 | Schuetz Thomas J. | CEO | Sell | 45.0 | -41,687 | -0.64% | ✗ | $145.9K |
| Jan 9, 2025 | Jan 13, 2025 | Schuetz Thomas J. | CEO | Sell | 45.0 | -58,054 | -0.88% | ✗ | $108K |
| Dec 9, 2024 | Dec 10, 2024 | Shin Barry | CFO | Neutral | 90.0 | +400,000 | 100.00% | ✗ | - |
| Dec 10, 2024 | Shin Barry | CFO | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Dec 10, 2024 | Lerner Neil | VP Finance | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Aug 13, 2024 | Aug 14, 2024 | Anderman Jonathan | Sr VP, Gen Counsel & Corp Sec | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Aug 9, 2024 | Anderman Jonathan | Sr VP, Gen Counsel & Corp Sec | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Mar 8, 2024 | Mar 11, 2024 | Boylan James P | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Feb 9, 2024 | Feb 14, 2024 | GRAY MARY ANN | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Feb 9, 2024 | Feb 14, 2024 | LINDAHL RICHARD S | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Feb 9, 2024 | Feb 14, 2024 | GORDON CARL L | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Feb 9, 2024 | Feb 14, 2024 | Chiniara Ellen | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Feb 9, 2024 | Feb 14, 2024 | Ferneau Philip | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Feb 8, 2024 | Feb 9, 2024 | Bisker-Leib Vered | CEO | Sell | 42.5 | -49,198 | -1.55% | ✗ | $71.3K |
| Feb 8, 2024 | Feb 9, 2024 | Schuetz Thomas J. | President | Sell | 45.0 | -44,782 | -0.68% | ✗ | $64.9K |
| Jan 9, 2024 | Jan 10, 2024 | Bisker-Leib Vered | CEO | Neutral | 90.0 | +1,753,125 | 123.42% | ✗ | - |
| Jan 9, 2024 | Jan 10, 2024 | Schuetz Thomas J. | President | Neutral | 90.0 | +637,500 | 10.66% | ✗ | - |
| Nov 17, 2023 | Nov 21, 2023 | Bisker-Leib Vered | COO | Sell | 42.5 | -64,415 | -4.34% | ✗ | $96.6K |
| Nov 17, 2023 | Nov 21, 2023 | Schuetz Thomas J. | CEO | Sell | 45.0 | -44,025 | -0.73% | ✗ | $66K |
| Apr 21, 2023 | Apr 24, 2023 | LINDAHL RICHARD S | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Apr 24, 2023 | LINDAHL RICHARD S | Director | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Mar 10, 2023 | Mar 10, 2023 | Schuetz Thomas J. | CEO | Buy | 56.3 | +10,000 | 0.17% | ✗ | $33.7K |
| Feb 27, 2023 | Feb 27, 2023 | Schuetz Thomas J. | CEO | Buy | 65.0 | +20,000 | 0.33% | ✗ | $79.6K |
| Feb 15, 2023 | Feb 15, 2023 | Schuetz Thomas J. | CEO | Buy | 65.0 | +20,000 | 0.33% | ✗ | $77.2K |
| Feb 8, 2023 | Feb 10, 2023 | WURZER DAVID M | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Feb 10, 2023 | WURZER DAVID M | Director | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Feb 8, 2023 | Feb 9, 2023 | Chiniara Ellen | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Feb 8, 2023 | Feb 9, 2023 | GRAY MARY ANN | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Feb 8, 2023 | Feb 9, 2023 | GORDON CARL L | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Feb 8, 2023 | Feb 9, 2023 | Ferneau Philip | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Feb 8, 2023 | Feb 9, 2023 | Schuetz Thomas J. | CEO | Neutral | 85.0 | +500,000 | 9.14% | ✗ | - |
| Feb 8, 2023 | Feb 9, 2023 | Bisker-Leib Vered | COO | Neutral | 90.0 | +400,000 | 36.87% | ✗ | - |
| Jan 31, 2023 | Jan 31, 2023 | Schuetz Thomas J. | CEO | Buy | 65.0 | +20,000 | 0.37% | ✗ | $81K |
| Jan 24, 2023 | Jan 24, 2023 | Schuetz Thomas J. | CEO | Buy | 65.0 | +20,000 | 0.37% | ✗ | $83.8K |
| Nov 22, 2022 | Nov 25, 2022 | Bisker-Leib Vered | COO | Sell | 42.5 | -24,500 | -2.26% | ✗ | $103.7K |
| Nov 18, 2022 | Nov 22, 2022 | Bisker-Leib Vered | COO | Sell | 42.5 | -22,261 | -1.01% | ✗ | $97K |
| Nov 10, 2022 | Boylan James P | Director | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Nov 8, 2022 | Nov 10, 2022 | ORBIMED ADVISORS LLC | Director | Buy | 92.5 | +402,000 | 2.71% | ✗ | $1.3M |
| Nov 8, 2022 | Nov 10, 2022 | GORDON CARL L | Director | Buy | 92.5 | +402,000 | 2.71% | ✗ | $1.3M |
| Sep 28, 2022 | Sep 28, 2022 | Schuetz Thomas J. | CEO | Buy | 56.3 | +10,000 | 0.18% | ✗ | $23.2K |
| Sep 26, 2022 | Sep 27, 2022 | Schuetz Thomas J. | CEO | Buy | 61.3 | +15,000 | 0.28% | ✗ | $34.1K |
| Sep 7, 2022 | Sep 8, 2022 | Schuetz Thomas J. | CEO | Buy | 61.3 | +15,000 | 0.28% | ✗ | $45.5K |
| Sep 1, 2022 | Sep 1, 2022 | Schuetz Thomas J. | CEO | Buy | 61.3 | +15,000 | 0.28% | ✗ | $42.5K |
| Aug 17, 2022 | Aug 17, 2022 | Schuetz Thomas J. | CEO | Buy | 61.3 | +15,000 | 0.28% | ✗ | $45.8K |
| Aug 10, 2022 | Aug 10, 2022 | Schuetz Thomas J. | CEO | Buy | 61.3 | +15,000 | 0.28% | ✗ | $39.6K |
| Aug 1, 2022 | Aug 2, 2022 | Schuetz Thomas J. | CEO | Buy | 61.3 | +15,000 | 0.28% | ✗ | $38.7K |
| Jun 21, 2022 | Jun 21, 2022 | Schuetz Thomas J. | CEO | Buy | 65.0 | +20,000 | 0.38% | ✗ | $56K |
| Jun 16, 2022 | Jun 17, 2022 | Schuetz Thomas J. | CEO | Buy | 61.3 | +20,000 | 0.38% | ✗ | $46.8K |
| Jun 13, 2022 | Jun 13, 2022 | Schuetz Thomas J. | CEO | Buy | 72.5 | +30,000 | 0.57% | ✗ | $68.7K |
| Jun 6, 2022 | Jun 7, 2022 | Schuetz Thomas J. | CEO | Buy | 72.5 | +30,000 | 0.57% | ✗ | $84.9K |
| Jun 1, 2022 | Jun 1, 2022 | Schuetz Thomas J. | CEO | Buy | 65.0 | +20,000 | 0.38% | ✗ | $60.6K |
| May 26, 2022 | May 26, 2022 | Schuetz Thomas J. | CEO | Buy | 65.0 | +20,000 | 0.39% | ✗ | $60.8K |
| May 23, 2022 | May 24, 2022 | Schuetz Thomas J. | CEO | Buy | 61.3 | +18,355 | 0.35% | ✗ | $49.9K |
| May 17, 2022 | May 17, 2022 | Schuetz Thomas J. | CEO | Buy | 61.3 | +20,215 | 0.39% | ✗ | $49.9K |
| May 11, 2022 | May 13, 2022 | GORDON CARL L | Director | Buy | 85.0 | +192,516 | 1.32% | ✗ | $420.5K |
| May 11, 2022 | May 13, 2022 | ORBIMED ADVISORS LLC | Director | Buy | 85.0 | +192,516 | 1.32% | ✗ | $420.5K |
| May 6, 2022 | May 10, 2022 | ORBIMED ADVISORS LLC | Director | Buy | 72.5 | +125,359 | 0.86% | ✗ | $197.3K |
| May 6, 2022 | May 10, 2022 | GORDON CARL L | Director | Buy | 72.5 | +125,359 | 0.86% | ✗ | $197.3K |
| May 10, 2022 | May 10, 2022 | Schuetz Thomas J. | CEO | Buy | 72.5 | +27,836 | 0.54% | ✗ | $50.1K |
| Apr 26, 2022 | Apr 28, 2022 | GRAY MARY ANN | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Apr 28, 2022 | GRAY MARY ANN | Director | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Apr 26, 2022 | Apr 28, 2022 | Chiniara Ellen | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Apr 28, 2022 | Chiniara Ellen | Director | Neutral | 52.5 | - | 0.00% | ✗ | - | |
| Feb 18, 2022 | Feb 23, 2022 | Ferneau Philip | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Feb 18, 2022 | Feb 23, 2022 | GORDON CARL L | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Feb 18, 2022 | Feb 23, 2022 | Kaplan Brett | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Feb 18, 2022 | Feb 23, 2022 | SQUINTO STEPHEN P | Director | Neutral | 52.5 | - | 0.00% | ✗ | - |
| Feb 18, 2022 | Feb 23, 2022 | Kalled Susan | Chief Scientific Officer | Neutral | 52.5 | - | 0.00% | ✗ | - |